P53 missense mutants collaborate with NRF2 to activate proteasome gene transcription in breast cancer, leading to resistance against the proteasome inhibitor carfilzomib and lipid nanocapsules.143, 144. The gene discussed is NFE2L2; the disease is breast cancer.